Our Technologies

The AggreGuide A-100 platelet function analyzer measures platelet aggregation using patented light-scattering technology. A laser beam is directed into the disposable cartridge where the blood sample is mixed with the selected reagent agonist. The system identifies platelet aggregation by measuring light-scattering against the background of other components of the whole blood.

With the A-100 system, a small sample of unprocessed whole blood from a standard blue top tube (citrate) is simply added to the disposable test cartridge that contains the freeze-dried test reagent. The system automatically conducts the test, and in a few minutes, the results are displayed on the A-100 screen.

The numerical result is termed “Platelet Activity Index”, abbreviated “PAI”, and gives an indication of the relative tendency of an individual’s platelets to aggregate.

Clinically, in determining whether or not an anti-platelet drug is working appropriately to cause platelet dysfunction in a patient, the PAI value is compared to a “cut-point” value. If the observed PAI is below the cut-point, then the determination is made that platelet dysfunction exists. If the observed PAI is above the cut-point, then the determination is made that platelet dysfunction is absent.

 

Industry References/Papers

Platelets play an important role in thrombosis and hemostasis. Understanding and modulating their reactivity is central to the management of patients with certain pathologies.
Aggredyne PFT White Paper
 
Importance of Platelet Function Testing with AggreGuide A-100 amid the COVID-19 Outbreak.
PFT-COVID19
 
Ramos-Cejudo J, Johnson,A.D., Beiser A, et al. Platelet Function Testing Is Associated with Dementia Risk in the Framingham Heart Study.  Journal of American Heart Association.2022;11:e023918 26 Apr 2022.
https://pubmed.ncbi.nlm.nih.gov/35470685/
 
Cofer LB, Barrett TJ, and Berger JS Aspirin for the Primary Prevention of Cardiovascular Disease: Time for a Platelet-Guided Approach.
Arteriosclerosis, Thrombosis, and Vascular Biology. 2022; 42:1207-1216
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9484763/
 
McFadyen JD and Gardiner EE. An Aspirin a Day….
Arteriosclerosis, Thrombosis, and Vascular Biology. 2022;42:1217-1219.
https://www.ahajournals.org/doi/full/10.1161/ATVBAHA.122.318337
 
Gurbel PA, Tantry U, Blideen K, Fisher R, Sukavaneshvar S, Dahen J,Speros,O. Novel Method for Assessing Platelet response to ADP: Technical Validation Study of the AggreGuide A-100 ADP Assay.
ACC.20 Am College of Cardiology eAbstract 28 Mar 2020
https://doi.org/10.1016/S0735-1097(20)30785-3
 
Gurbel P.A., Tantry U.S., Bliden K.P. et al. Clinical validation of AggreGuide A-100 ADP, a novel assay for assessing the antiplatelet effect of oral P2Y12 antagonists. J Throm & Thrombolysis. 2021; 52,272-280.
https://doi.org/10.1007/s11239-021-02498-0
 
Ramos-Cejudo J., Johnson A.D., Beiser A. et al. Platelet Function is Associated with Dementia Risk in the FRAMINGHAM HEART STUDY. J Am Heart Assoc. 2022; May 3; 11(9).
https://www.ahajournals.org/doi/10.1161/JAHA.121.023918
 
Li W, Zhu W, Wang A, et al. Effect of Adjusting Antiplatelet Therapy on Preventing Ischemic Events After Stenting for Intracranial Aneurysms. Stroke. 2021; 52: 3815-3825.
https://www.ahajournals.org/doi/10.1161/STROKEAHA.120.032989
 
Chapot,R. Platelet Function Testing Is Required for Intracranial Stent Placement. STROKE. 2021; 52:00-00.
https://www.ahajournals.org/doi/10.1161/STROKEAHA.121.036457
 
Galli M, Benenati S, Capodanno D…Angiolillo D J et al. Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systemic review and menta-analysis. LANCET 2021; 397: 1470-83.
https://doi.org/10.1016/S0140-6736(21)00533-X
error: